How mass tort firms source and sign claimants in 2026 — the channels, the funnel math, and the cost-per-signed-retainer system that decides whether a litigation pays.
What you're actually buying isn't a lead — it's a signed, qualified retainer
Most mass tort marketing fails for one reason: the firm optimizes for the wrong unit. Lead volume looks like progress on a dashboard, but a lead is not a case. The unit that pays your bills is a signed retainer that clears your case criteria and survives the medical-record and product-identification check months later.
The gap between those two numbers is brutal. A large share of raw leads never become qualified prospects, and a meaningful share of the prospects who do qualify never sign. Stack those stages and only a small slice of the forms and calls you generate turn into retained cases — the exact slice depends entirely on how rigorous your screening and intake are. Everything in between is noise your staff has to wade through, and you're paying for all of it.
This is why "more leads" is a trap. If your screening is loose, doubling your lead volume just doubles the junk your intake team processes and the budget you burn on people who were never going to qualify. The whole system has to be built backward from the signed retainer: case criteria defined first, screening built into the front of the funnel, and every dollar measured against cost per signed case — not cost per lead. A firm that signs a tight, screened set of cases will beat a firm drowning in cheap, unscreened volume every time. Build the system to qualify, not to collect.
The economics start with the litigation, not the marketing
Before you spend a dollar, the active litigation sets your ceiling. Mass tort isn't one market — it's dozens of separate micro-markets, each with its own claimant value, competition level, and shelf life. A campaign that prints money on one tort loses money on the next, and the difference often has nothing to do with your ads.
Three forces govern every litigation. First, the expected case value and your fee — contingency fees in mass tort commonly run around a third before a case is in suit and rise once it proceeds past filing, so a signed claimant's worth depends on settlement projections that may be years out. These cases routinely take years, not months, to resolve, which means you're financing acquisition today against revenue that may not arrive until well after the campaign runs. Second, the competitive cost to acquire, which swings widely by tort and geography — an emerging litigation few firms are bidding on behaves nothing like a saturated one where everyone is chasing the same claimants. Third, where the litigation sits on the MDL calendar. The federal MDL landscape is large — roughly 160 active dockets carrying just under 200,000 pending actions as of mid-2026 — and bellwether trial dates and key rulings move both settlement expectations and lead pricing in real time.
The practical takeaway: model each litigation as its own P&L. An emerging tort with low public awareness may have cheap leads but require patient market education; a saturated tort where every firm is bidding the same claimants pushes acquisition costs up fast. Don't run a single 'mass tort' budget. Run a portfolio, fund the litigations where your cost per signed case clears your projected fee, and pull spend the moment a docket cools.
The four channels that feed a qualified-claimant pipeline
A working mass tort system runs four channels into one pipeline, each doing a job the others can't. The mistake is treating them as separate campaigns with separate vendors; they only compound when one team wires them together.
Paid search captures claimants at the moment of intent — people typing 'do I qualify for a lawsuit' or '[drug] lawyer near me.' This is your fastest channel and your most expensive: legal keywords are among the priciest in all of search, and mass tort and personal-injury terms sit near the top of that list. You pay for speed, so paid search earns its place when you're racing to source an active docket. Paid social — Meta, and increasingly short-form video — does something search can't: it reaches injured people who don't yet know a lawsuit exists, typically at a far lower cost per lead. Search harvests demand that already exists; social creates it.
SEO and AI search are the compounding layer. National and local organic rankings, eligibility content for each litigation, and a tuned Google Business Profile bring in claimants you don't pay per click for — and increasingly, the answer engines (Google's AI Overviews, ChatGPT, Gemini, Perplexity) decide which firms get named when someone asks who to call. These take months to mature, which is exactly why you start them on day one rather than when the paid budget gets tight. The fourth channel — reviews and reputation — isn't a traffic source, it's the trust signal that lifts conversion across the other three. Run them as one system and a claimant who clicks an ad, reads your eligibility page, and sees a wall of credible reviews converts at a multiple of a claimant who hits a thin landing page cold.
Screening belongs at the front of the funnel, not the intake desk
The single highest-leverage decision in a mass tort system is where you put the screening. Firms that screen at the intake desk pay — in staff hours, in slow response, in burnout — for every unqualified person who slipped through the ad. Firms that screen on the landing page filter before a human is ever involved.
A claim-specific landing page — one per active litigation, never a generic 'contact us' page — does the qualifying work. It states the eligibility criteria plainly (the product, the injury, the exposure window, the surgery or diagnosis), then uses a progressive form that asks the disqualifying questions early. Someone who used the device outside the date range, or never had the qualifying procedure, gets filtered or routed differently before they hit your intake queue. The page also has to do this compliantly: required attorney-advertising disclaimers, and TCPA-compliant consent language so that the moment someone submits a form, you have documented permission to call and text. Under ABA Model Rule 5.3, your firm is responsible for the conduct of the non-lawyers and vendors marketing on its behalf — a sloppy lead-gen page is your liability, not the agency's.
Good screening is also where speed gets won, because a pre-qualified lead is one your intake team can act on in seconds instead of triaging. The economics are direct: tighter front-end screening lifts your qualified ratio, which compresses cost per signed case across the whole campaign. This is the unglamorous core of the system. It's rarely the ad creative or the keyword list that separates a profitable litigation from a money pit — it's whether the people reaching your intake team actually qualify.
Speed-to-lead is the conversion lever you control completely
In mass tort, claimants almost never contact one firm. They fill out three or four forms in a sitting, and the firm that responds first and qualifies them fastest is usually the one that signs them. This makes intake speed the single conversion variable you fully control — no auction, no algorithm, just your response time.
The direction of the data is well established in legal intake: responding within the first few minutes lifts your odds of reaching and converting a lead dramatically, and the odds fall off sharply once you let a submission sit. A lead you paid for and answer two hours later is, for practical purposes, a lead you bought for a competitor. That's why a serious system pairs the marketing with the plumbing: instant auto-response on form submit, missed-call text-back that fires the moment a call goes unanswered, and routing that puts a live, trained intake person on the qualified ones first.
Follow-up matters as much as first response, because the claimant who doesn't sign on call one isn't gone — they're undecided. Automated, compliant nurture sequences (case-review confirmations, qualification updates, retainer reminders) keep them engaged through the days it takes to gather records and sign. The firms that win mass tort aren't always the ones with the biggest ad budget; they're the ones whose intake never sleeps. If you're going to invest anywhere beyond the ads themselves, invest here — it's the cheapest way to raise the return on spend you're already making.
The metrics that actually run the system
You cannot manage a mass tort program on cost per lead. It's a vanity number that hides whether you're signing cases or just collecting forms. The metrics that run the system tie marketing spend to signed, qualified retainers — by litigation.
Start with cost per signed case, calculated honestly: your total spend on a litigation divided by the number of cases that actually signed and cleared your criteria. That single figure — not your cost per lead — is what you compare against the fee the litigation projects. Track it per docket, because a blended average across torts will tell you nothing useful; one litigation can be quietly subsidizing another that should be cut. Then layer source attribution so every signed retainer traces back to the exact channel, keyword, and campaign that produced it — call tracking, form tracking, and conversion tracking wired in from day one, not retrofitted after the fact.
Two operational metrics keep the rest honest. Speed-to-lead — your median time to first response — tells you whether you're losing signed cases to competitors before the marketing even gets credit. And call outcomes, recorded and scored for qualification and signing, surface the leads your intake team is mishandling, which is often a bigger leak than anything in the ad account. The point of this measurement isn't reporting for its own sake; it's that mass tort is a portfolio you actively manage. You scale the litigations and channels where cost per signed case clears your projected fee, and you cut the ones that don't — fast, before the docket and the spend get away from you. A transparent setup where you own the ad accounts, the data, and the attribution is what makes that decision possible at all.
Compliance isn't a footnote — it's a load-bearing part of the system
Legal advertising is regulated in ways ordinary lead-gen isn't, and in mass tort — where campaigns run across many states at once — the rules multiply. Treat compliance as infrastructure, because a violation can cost you ad accounts, bar standing, or exposure far worse than a wasted budget.
Three layers stack. First, state bar advertising rules: states adapt the ABA Model Rules differently, so disclaimer requirements, restrictions on past-results and testimonial claims, and what you can say about 'qualifying' vary by jurisdiction. A multi-state tort campaign has to satisfy the strictest states it touches. Second, the TCPA: consent to call and text must be clearly disclosed and documented at the point of capture — a bare form submission isn't blanket permission, and enforcement keeps tightening, which raises the stakes for firms generating leads across state lines. Third, and most overlooked, ABA Model Rule 5.3 makes your firm responsible for the marketing and intake conducted on its behalf. If a lead vendor or agency cuts a corner on a landing page or an unconsented robocall, the liability lands on your license, not theirs.
The practical implication for how you build the system: bake compliance into the pages, the consent language, and the call scripts up front, with review built into the launch process — not bolted on after a complaint. It's also a reason the scattered-vendor model is risky. When five vendors each touch a piece of your funnel, no one owns compliance end to end. A single team running the landing pages, ads, intake, and tracking can keep disclaimers, consent, and state-by-state rules consistent across every active litigation — which is the approach SearchPod takes, and the only way the rest of the system stays defensible at scale.
Want help implementing this?
Get a free proposal for your content marketing setup. We’ll show you exactly where the opportunities are.
Get Free ProposalRelated Articles